A Phase III multicentre, randomized, double-blind trial to evaluate the efficacy and safety of oral contezolid versus linezolid in adults with complicated skin and soft tissue infections

In Vitro Activity and Potency of the Novel Oxazolidinone Contezolid (MRX-I) Tested against Gram-Positive Clinical Isolates from US and Europe

(2020) Cecilia G. Carvalhaes et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Optimizing the Clinical Use of Vancomycin

(2016) Rocío Álvarez et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Epidemiology and microbiology of skin and soft tissue infections

(2016) Silvano Esposito et al.   CURRENT OPINION IN INFECTIOUS DISEASES

A retrospective study of the risk factors for linezolid-induced thrombocytopenia and anemia

(2016) Yuki Hanai et al.   JOURNAL OF INFECTION AND CHEMOTHERAPY

Managing skin and soft-tissue infection and nosocomial pneumonia caused by MRSA: a 2014 follow-up survey

(2015) Matthew Dryden et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

In VivoAntibacterial Activity of MRX-I, a New Oxazolidinone

(2014) Cong-Ran Li et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

New Potent Antibacterial Oxazolidinone (MRX-I) with an Improved Class Safety Profile

(2014) Mikhail F. Gordeev et al.   JOURNAL OF MEDICINAL CHEMISTRY

Methicillin-Resistant Staphylococcus aureus Therapy: Past, Present, and Future

(2013) K. A. Rodvold et al.   CLINICAL INFECTIOUS DISEASES

Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant Staphylococcus aureus Infections in Adults and Children

(2011) Catherine Liu et al.   CLINICAL INFECTIOUS DISEASES